Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency

NCT03408132 is registered in ClinicalTrials.gov with GlyPharma Therapeutics as lead sponsor.

NCT NCT03408132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03408132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency
Lead sponsor
GlyPharma Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
May 2, 2018
Completion date
October 28, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sbs - short bowel syndrome